EUVIMEDEUVIMED entdecken
Crossref

Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck

Kazuki Yokoyama iD, Koichiro Wasano iD, Keita Sasaki iD, Ryunosuke Machida, Mitsuhiko Nakahira, Koji Kitamura, Tomofumi Sakagami, Naohiro Takeshita, Akira Ohkoshi, Motoyuki Suzuki, Ichiro Tateya, Yohei Morishita und 8 weitere

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Kazuki Yokoyama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Palliative Care, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Cancer Center Research and Development Funds, Research Fund of National Federation of Health Insurance Societies (Kenpo-ren).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan.

Methods

From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied.

Results

The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens’ first-month costs were 612 851–849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000–800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN.

Conclusion

First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Palliative CareSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsNeoplasm Recurrence, LocalHumansJapanMaleAgedFemaleMiddle AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAdultRetrospective StudiesNeoplasm Metastasis

Stichwörter der Autor:innen

costhead and neck cancerhealth expendituresimmune checkpoint inhibitorpalliative chemotherapy

Autor:innen und Institutionen

  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Otolaryngology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Head and Neck Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Osaka, Japan.

ORCID-Profile: Kazuki Yokoyama, Koichiro Wasano, Keita Sasaki, Satoru Miyamaru, Naomi Kiyota

Förderung

  • National Cancer Center Research and Development Funds
  • Research Fund of National Federation of Health Insurance Societies (Kenpo-ren)

Zitieren

APA

Yokoyama, K., Wasano, K., Sasaki, K., Machida, R., Nakahira, M., Kitamura, K., Sakagami, T., Takeshita, N., Ohkoshi, A., Suzuki, M., Tateya, I., Morishita, Y., Sekimizu, M., Nakayama, M., Koyama, T., Shibata, H., Miyamaru, S., Kiyota, N., Hanai, N., & Homma, A. (2024). Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae117

Vancouver

Yokoyama K, Wasano K, Sasaki K, Machida R, Nakahira M, Kitamura K, et al. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae117

BibTeX
@article{Yokoyama2024,
  author = {Yokoyama, Kazuki and Wasano, Koichiro and Sasaki, Keita and Machida, Ryunosuke and Nakahira, Mitsuhiko and Kitamura, Koji and Sakagami, Tomofumi and Takeshita, Naohiro and Ohkoshi, Akira and Suzuki, Motoyuki and Tateya, Ichiro and Morishita, Yohei and Sekimizu, Mariko and Nakayama, Masahiro and Koyama, Taiji and Shibata, Hirofumi and Miyamaru, Satoru and Kiyota, Naomi and Hanai, Nobuhiro and Homma, Akihiro},
  title = {Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae117}
}
Kostenlos starten →